Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19644566 | 0.90 | POLRMT (0.36) | POLRMTP2RX1P2RX3P2RX4RNASEL | |
| SCHEMBL19644577 | 0.84 | RNASEL (0.31) | P2RX1P2RX3P2RX4RNASEL | |
| SCHEMBL21880479 | 0.83 | POLRMT (0.35) | POLRMTP2RX1P2RX3P2RX4RNASEL | |
| SCHEMBL19644592 | 0.81 | HIF1A (0.30) | — | |
| SCHEMBL17453492 | 0.77 | POLRMT (0.54) | POLRMTP2RX1P2RX3P2RX4RNASEL | |
| SCHEMBL19644584 | 0.77 | POLRMT (0.54) | POLRMTP2RX1P2RX3P2RX4RNASEL | |
| SCHEMBL17453490 | 0.77 | POLRMT (0.54) | POLRMTP2RX1P2RX3P2RX4RNASEL | |
| SCHEMBL19644595 | 0.77 | RNASEL (0.33) | POLRMTP2RX1P2RX3P2RX4RNASEL | |
| SCHEMBL21137369 | 0.74 | POLRMT (0.54) | POLRMTP2RX1P2RX3P2RX4RNASEL | |
| SCHEMBL17453487 | 0.74 | POLRMT (0.54) | POLRMTP2RX1P2RX3P2RX4RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194223-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9828388-B2 | Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-D]pyrimidines useful for treating respiratory syncitial virus infections | GILEAD SCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194223-A1 | THIENO[3,2-d]PYRIMIDINE, FURO[3,2-d]PYRIMIDINE, AND PYRROLO[3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | DPYD, TYMS, TYMP | POLRMT 105/4885P2RX1 68/4885P2RX3 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.